On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
The company's Refinitiv ESG score, based on a ranking of the company relative to its industry, comes out particularly well.
Highlights: Bristol-Myers Squibb Company
Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
The company returns high margins, thereby supporting business profitability.
Given the positive cash flows generated by its business, the company's valuation level is an asset.
The company is one of the best yield companies with high dividend expectations.
Sales forecast by analysts have been recently revised upwards.
The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
Weaknesses: Bristol-Myers Squibb Company
As estimated by analysts, this group is among those businesses with the lowest growth prospects.
The group shows a rather high level of debt in proportion to its EBITDA.
In relation to the value of its tangible assets, the company's valuation appears relatively high.
For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
Over the past twelve months, analysts' opinions have been revised negatively.
Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.